基調講演

2017年10月11日(水) 10:00-11:30

アネックスホール
F203-F206

同時通訳

BioScience and Technology development in Singapore, Policy and Outcome

Prof. Sir David Lane

Chief Scientist, A*STAR; Director, p53 Lab

Under the last five-year Research, Innovation and Enterprise (RIE) 2015 Plan, the Singapore government committed $16 billion over 2011 to 2015 to establish Singapore as a global research and development (R&D) hub. The government is sustaining its commitment to research, innovation and enterprise, and will invest $19 billion for the RIE2020 Plan over 2016 to 2020. In addition to large investments in the research universities the government also supports, through the Ministry of Trade and Industry ( MTI ) A*STAR the Agency for Science Technology and Research, which has a particular goal to work with industry encouraging development, investment, and the creation high value jobs.

On 29 September 2003, A*STAR opened Biopolis, Singapore’s hub for the biomedical sciences. A*STAR's nine biomedical research institutes and centres are located at Biopolis, along with other corporate research labs by companies such as Chugai, Danone, Abbott and Procter &Gamble. Over the years, the biomedical sector in Singapore has expanded in tandem with Biopolis. In 2000, the sector contributed 10 per cent to Singapore's manufacturing value-add. In April 2017, biomedical manufacturing was the second largest contributor to total manufacturing value-add at 19.6 per cent. A*STAR collaborates with industry partners, public sector agencies and the wider research community to drive innovation and enterprise for Singapore. Between 2011 – 2015, A*STAR worked on 8,965 industry projects, almost six times that of the previous five-year tranche of 1,547. This has resulted in more than S$1.6 billion in industry R&D spending. A*STAR also signed 1,030 licensing agreements over the same period, of which 70 per cent were signed with local SMEs. At the start of Biopolis a big push was made by the then Chairman Philip Yeo to both attract international talent and at the same time support a strong scholarship program to build local talent. Incentives were also put in place in combination with the Economic Development Board to attract international companies to establish not only manufacture but also do research in Singapore. In this talk I will discuss these developments, the success and well as the occasional disappointments and consider what lessons have been learned and whether the Singapore model has general application or is tied to the unique human environment of the “Little Red Dot”.

このウィンドウを閉じる